Business Wire

Alma Technologies Launches Scalable Encoder and Decoder Semiconductor IP for VESA DSC 1.2b Visually Lossless Compression

30.3.2022 15:01:00 EEST | Business Wire | Press release

Share

IP Highlights:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005026/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Extending Alma Technologies UHT™ Image & Video Compression product line, the new UHT-DSC-E and UHT-DSC-D IP cores provide ultra-low latency visually lossless compression across display interfaces and devices. (Graphic: Business Wire)

- Fully compliant with VESA DSC 1.2b and backwards compatible with DSC 1.1

- Ultra-low latency visually lossless image compression for all types of content

- Scalable architecture supporting up to 10K @120Hz with native pixel coding and up to 16 bits per color for high color depth and HDR content

- Compatible with major transport standards including MIPI DSI, VESA DisplayPort 1.4 and HDMI 2.1

Alma Technologies S.A. today announced its new UHT-DSC-E and UHT-DSC-D DSC 1.2b encoder and decoder IP cores that enable the transport of high-definition content with up to 10K resolution, 120Hz refresh rate, high dynamic range and high color depth through existing interfaces, such as VESA DisplayPort, MIPI DSI and HDMI 2.1.

Extending Alma Technologies UHTTM Image and Video Compression family of JPEG, JPEG 2000 and H.264 IP, these ultra-high throughput and scalable performance semiconductor IP implementations of the DSC 1.2b standard provide a fully accelerated, standalone and robust compression solution in a single IP instance, saving on ASIC or FPGA silicon area and power. The cores do not need an external memory device for their implementation and lower power consumption for longer battery life is further enabled by the reduced video interface data rates and video buffer sizes.

The new Alma Technologies encoder and decoder IP cores for DSC 1.2b are very easy-to-use and integrate in a system. They are self-contained, CPU-less, complete H/W implementations and are available either in RTL source code, or as pre-synthesized Netlists for all major FPGA vendor devices.

Contact us online at www.alma-technologies.com/contact, or call us at +30-210-603-9850 to learn more.

About Alma Technologies

Alma Technologies is a semiconductor IP provider, designing high-quality FPGA and ASIC IP cores since 2001. Its products stand out for their engineering, being complete, easy-to-use and reliable IP solutions. World-class technical support and a long track record of proven designs by more than 250 licensees in over 20 countries provide Alma Technologies customers with excellent service and great value.

UHT is a trademark of Alma Technologies.

All other trademarks and trade names are the property of their respective owners.

###

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Vassilis Spiliotopoulos
media@alma-technologies.com
+30-210-603-9850 ext.107

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level

Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release

Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett

HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 18:30:00 EEST | Press release

HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye